Clinical trials: Toripalimab, completed
Solid Tumor, Neoplasms
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1…
- Conditions
- Solid Tumor, Neoplasms, Malignant Tumor
- Trial name
- NCT04991506
- Testing
- ES102, JS001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Elpiscience Biopharma, Ltd.
Huge Hepatocellular Carcinoma (HCC) (>10cm)
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system.
- Trial name
- NCT07639294
- Testing
- hepatectomy without immune checkpoint inhibitors-based adjuvant therapy, hepatectomy with immune checkpoint inhibitors-based adjuvant therapy, neoadjuvant conversion therapy followed by surgery
- Where
- China
- Volunteers
- 715 people
- Sponsor
- Tongji Hospital
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
This is one randomized, double-blind, multi-center, placebo-controlled phase III study. The objective of this study is to compare the effectiveness and safety of JS001 combined with paclitaxel and cisplatin(TP regimen )with…
- Trial name
- JUPITER06 (NCT03829969)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 514 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer
This is a pre-surgical study involving subjects with muscle invasive bladder urothelial cancer, who are candidates for cisplatin ineligible neoadjuvant therapy. It is a one-arm phase II study in single center.
- Trial name
- NCT04553939
- Testing
- Toripalimab, Gemcitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma
Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC). However, the station-specific distribution of residual lymph node metastasis after NCIT remains…
- Conditions
- Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis
- Trial name
- NCT07902544
- Volunteers
- 717 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Advanced Solid Tumor
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid…
- Trial name
- NCT05188664
- Testing
- LM-302, Toripalimab
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- LaNova Australia Pty Limited
Advanced Melanoma
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
A phase I clinical study evaluating LBL-007 in the treatment of subjects with advanced solid tumors
- Trial name
- NCT04640545
- Testing
- LBL-007, Toripalimab, Axitinib Tablets
- Where
- 7 sites in China
- Volunteers
- 79 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
High-Risk Resectable NSCLC
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor…
- Trial name
- NCT03732664
- Testing
- Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Solid Tumor
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
- Trial name
- NCT03874897
- Testing
- CAR-CLDN18.2 T-Cells, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 134 people
- Sponsor
- Peking University
Solid Tumors
Study of JS001 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerance and Dose-Limiting Toxicity (DLT) of Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with advanced solid tumors.
- Trial name
- NCT02857166
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Solid Tumor
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination with Chemotherapy or Toripalimab in Advanced Solid Tumors
- Trial name
- NCT05173142
- Testing
- HMPL-453, gemcitabine and cisplatin, toripalimab
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Hutchison Medipharma Limited
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Advanced Malignant Tumors
A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors
This is a single-arm, open-label, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, PK characteristics, immunogenicity and efficacy of LBL-007 in combination with Toripalimab in Treatment of Advanced…
- Trial name
- NCT05102006
- Testing
- LBL-007 Injection, Toripalimab Injection
- Where
- 14 sites in China
- Volunteers
- 80 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Treatment-naive Advanced Non-small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC
This is one randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with standard 1st-line chemotherapy in…
- Trial name
- NCT03856411
- Testing
- TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
- Where
- China
- Volunteers
- 465 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Small Cell Lung Cancer
Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer
This is a phase III, multicenter, double-blinded, placebo-controlled study of platinum（Cisplatin or Carboplatin） plus etoposide with or without toripalimab as first Line therapy in patients with extensive stage small cell lung…
- Trial name
- NCT04012606
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Metastatic Colorectal Adenocarcinoma
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial.
- Trial name
- NCT05942768
- Testing
- regorafenib plus anti-PD-1 antibodies
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Hunan Cancer Hospital
Biliary Tract Cancer
A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer
1. Target population: patients with advanced biliary tract cancer (including gallbladder carcinoma, intrahepatic and extrahepatic cholangiocarcinoma) . 2.
- Trial name
- NCT03796429
- Testing
- GS+Toripalimab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Non Small Cell Lung Cancer
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
The aim of the study was to investigate the efficacy of Toripalimab Combined with Double Platinum Based Chemotherapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer.
- Trial name
- TOGATHER (NCT04144608)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yongchang Zhang
Sarcoma
Chidamide Combined With Toripalimab in Sarcoma
Soft tissue sarcoma is a relatively rare malignant tumor with an incidence of about 1-2/100,000. The best way to obtain evidence-based medical evidence is to participate in clinical trials with new drugs (especially targeted…
- Trial name
- NCT04025931
- Testing
- chidamide and toripalimab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sun Yat-sen University